Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIb Trial Evaluations Of The Effectiveness Of Treatment Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 (Pembrolizumab)

NCT02430363 is registered in ClinicalTrials.gov with Medical Research Council as lead sponsor.

NCT NCT02430363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02430363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIb Trial Evaluations Of The Effectiveness Of Treatment Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 (Pembrolizumab)
Lead sponsor
Medical Research Council
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 31, 2013
Completion date
June 30, 2018
Enrollment
58 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma